These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39181211)

  • 1. ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
    Liu YJ; Kimura M; Li X; Sulc J; Wang Q; Rodríguez-López S; Scantlebery AML; Strotjohann K; Gallart-Ayala H; Vijayakumar A; Myers RP; Ivanisevic J; Houtkooper RH; Subramanian GM; Takebe T; Auwerx J
    J Hepatol; 2024 Aug; ():. PubMed ID: 39181211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of rat hepatic α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase, a key enzyme in the tryptophan- NAD pathway, by dietary cholesterol and sterol regulatory element-binding protein-2.
    Matsuda H; Sato M; Yakushiji M; Koshiguchi M; Hirai S; Egashira Y
    Eur J Nutr; 2014; 53(2):469-77. PubMed ID: 25289390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice.
    Dixon ED; Claudel T; Nardo AD; Riva A; Fuchs C; Mlitz V; Busslinger G; Schnarnagl H; Stojakovic T; Senéca J; Hinteregger H; Grabner GF; Kratky D; Verkade H; Zimmermann R; Haemmerle G; Trauner M
    J Hepatol; 2024 Sep; ():. PubMed ID: 39357546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo NAD
    Katsyuba E; Mottis A; Zietak M; De Franco F; van der Velpen V; Gariani K; Ryu D; Cialabrini L; Matilainen O; Liscio P; Giacchè N; Stokar-Regenscheit N; Legouis D; de Seigneux S; Ivanisevic J; Raffaelli N; Schoonjans K; Pellicciari R; Auwerx J
    Nature; 2018 Nov; 563(7731):354-359. PubMed ID: 30356218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD
    Pellicciari R; Liscio P; Giacchè N; De Franco F; Carotti A; Robertson J; Cialabrini L; Katsyuba E; Raffaelli N; Auwerx J
    J Med Chem; 2018 Feb; 61(3):745-759. PubMed ID: 29345930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of mouse hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor alpha.
    Shin M; Kim I; Inoue Y; Kimura S; Gonzalez FJ
    Mol Pharmacol; 2006 Oct; 70(4):1281-90. PubMed ID: 16807375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of pyrazinamide and clofibrate on gene expression of rat hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme of the tryptophan-NAD pathway.
    Egashira Y; Sato M; Sato M; Sugawara R; Tanabe A; Shin M; Sanada H
    Int J Vitam Nutr Res; 2006 May; 76(3):138-46. PubMed ID: 17048193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACMSD mediated de novo NAD
    Zeng F; Zhou P; Wang M; Xie L; Huang X; Wang Y; Huang J; Shao X; Yang Y; Liu W; Gu M; Yu Y; Sun F; He M; Li Y; Zhang Z; Gong W; Wang Y
    Diabetes Res Clin Pract; 2023 Dec; 206():111014. PubMed ID: 37977551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic miR-149-5p upregulation fosters steatosis, inflammation and fibrosis development in mice and in human liver organoids.
    Correia de Sousa M; Delangre E; Berthou F; El Harane S; Maeder C; Fournier M; Krause KH; Gjorgjieva M; Foti M
    JHEP Rep; 2024 Sep; 6(9):101126. PubMed ID: 39263327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.
    Xu M; Zhao J; Zhu L; Ge C; Sun Y; Wang R; Li Y; Dai X; Kuang Q; Hu L; Luo J; Kuang G; Ren Y; Wang B; Tan J; Shi S
    J Hepatol; 2024 Sep; ():. PubMed ID: 39260704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells.
    Che L; Stevenson CK; Plas DR; Wang J; Du C
    bioRxiv; 2024 Sep; ():. PubMed ID: 39314445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of Human Dimeric α-Amino-β-Carboxymuconate-ε-Semialdehyde Decarboxylase Inhibition With TES-1025.
    Cianci M; Giacchè N; Cialabrini L; Carotti A; Liscio P; Rosatelli E; De Franco F; Gasparrini M; Robertson J; Amici A; Raffaelli N; Pellicciari R
    Front Mol Biosci; 2022; 9():834700. PubMed ID: 35463964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.